Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Other Accumulated Expenses (2021 - 2023)

Historic Other Accumulated Expenses for Kezar Life Sciences (KZR) over the last 3 years, with Q4 2023 value amounting to $106000.0.

  • Kezar Life Sciences' Other Accumulated Expenses fell 6000.0% to $106000.0 in Q4 2023 from the same period last year, while for Dec 2023 it was $106000.0, marking a year-over-year decrease of 6000.0%. This contributed to the annual value of $106000.0 for FY2023, which is 6000.0% down from last year.
  • Latest data reveals that Kezar Life Sciences reported Other Accumulated Expenses of $106000.0 as of Q4 2023, which was down 6000.0% from $265000.0 recorded in Q4 2022.
  • Kezar Life Sciences' Other Accumulated Expenses' 5-year high stood at $280000.0 during Q3 2021, with a 5-year trough of $99000.0 in Q4 2021.
  • For the 3-year period, Kezar Life Sciences' Other Accumulated Expenses averaged around $171500.0, with its median value being $141500.0 (2021).
  • As far as peak fluctuations go, Kezar Life Sciences' Other Accumulated Expenses soared by 16767.68% in 2022, and later crashed by 6000.0% in 2023.
  • Over the past 3 years, Kezar Life Sciences' Other Accumulated Expenses (Quarter) stood at $99000.0 in 2021, then soared by 167.68% to $265000.0 in 2022, then tumbled by 60.0% to $106000.0 in 2023.
  • Its Other Accumulated Expenses was $106000.0 in Q4 2023, compared to $265000.0 in Q4 2022 and $99000.0 in Q4 2021.